FDA clears Micronet's spinal cord lead:
This article was originally published in Clinica
Executive Summary
Micronet Medical has received US FDA 510(k) approval for what it claims is the smallest diameter neurostimulation lead on the market. The Axxess lead measures just 0.83mm in diameter and is designed for use with a spinal cord stimulation system for helping to manage chronic, intractable pain of the trunk and limbs. The market for treating pain via spinal stimulation was $200 million in 1999, and is expected to grow to over $400 million by 2003, says St Paul, Minnesota-based Micronet.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.